CAS 1446261-44-4

5,6,7a,11-Tetraazacyclohepta[def]cyclopenta[a]fluoren-4(7H)-one, 2-fluoro-5,8,9,10,10a,11-hexahydro-10a-methyl-, (10aR)-

CAS : 1446261-44-4

Formule : C₁₆H₁₅FN₄O

Degré de pureté : 99%

Couleur et forme : Solid

Masse moléculaire : 298.3149

Ref: IN-DA001JVA

Pamiparib

CAS : 1446261-44-4

Pamiparib

Degré de pureté : ≥98%

Masse moléculaire : 298.31g/mol

Ref: 54-BUP16275

Pamiparib

CAS : 1446261-44-4

Pamiparib (BGB-290) is an orally active, potent, highly selective PARP inhibitor. It has potent PARP trapping, and capability to penetrate the brain.

Formule : C₁₆H₁₅FN₄O

Degré de pureté : 99.69%

Couleur et forme : Solid

Masse moléculaire : 298.31

Ref: TM-T5058

Pamiparib

Produit contrôlé

CAS : 1446261-44-4

Pamiparib is a drug that is used to treat breast cancer and other solid tumours. It has been shown to inhibit the activity of the P-glycoprotein (P-gp) transporter, which prevents the escape of anticancer drugs from cells, resulting in increased concentrations of these drugs in tumour tissues. Pamiparib binds to the PDGFR-β receptor, inhibiting the growth factor epidermal growth factor (EGF). Pamiparib has been shown to be effective on resistant prostate cancer cells with high levels of EGF receptors. This drug also inhibits adenosine diphosphate ribose (ADPR) synthesis and platinum-based chemotherapy, as well as radiation therapy. The pharmacokinetic properties of pamiparib have been shown through plasma concentration–time curves for a single dose and multiple doses over time.

Formule : C₁₆H₁₅FN₄O

Degré de pureté : Min. 95%

Masse moléculaire : 298.32 g/mol

Ref: 3D-BP180190